Clinical Trial on the Safety and Tolerability of Personalized Cancer Vaccines Using Human Platelet Lysate-Induced Antigen-Presenting Cells

Clinical Trial on the Safety and Tolerability of Personalized Cancer Vaccines Using Human Platelet Lysate-Induced Antigen-Presenting Cells

Research and development of personalized cancer vaccines as precision medicine are ongoing. We predicted human leukocyte antigen (HLA)-compatible cancer antigen candidate peptides based on patient-specific cancer genomic profiles and performed a Phase I clinical trial for the safety and tolerability...

Full description

Bibliographic Details
Main Authors: Terutsugu Koya, Kenichi Yoshida, Misa Togi, Yo Niida, Sumihito Togi, Hiroki Ura, Shuichi Mizuta, Tomohisa Kato, Sohsuke Yamada, Takeo Shibata, Yi-Chang Liu, Shyng-Shiou Yuan, Deng-Chyang Wu, Hirohito Kobayashi, Taiju Utsugisawa, Hitoshi Kanno, Shigetaka Shimodaira
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Cancers
Subjects:
personalized cancer vaccine
in silico prediction
antigen-presenting cells
enzyme-linked immunosorbent assay
memory T cells
Online Access:https://www.mdpi.com/2072-6694/15/14/3627

Internet

https://www.mdpi.com/2072-6694/15/14/3627

Similar Items